LCTX R&D Expenses
Lineage Cell Therapeutics, Inc. Common Stock · R&D Expenses
LCTX R&D Expenses
Latest reported$20.52Mperiod ending
LCTX TTM R&D Expenses ($0.00 → $20.52M)
TTM R&D Expenses
High-resolution chart · PNG
LCTX r&d expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | R&D Expenses (USD) |
|---|---|
| 20,517,000 | |
| 18,849,000 | |
| 17,729,000 | |
| 12,914,000 | |
| 12,814,000 | |
| 12,576,000 | |
| 12,450,000 | |
| 12,901,000 | |
| 13,471,000 | |
| 14,476,000 | |
| 15,673,000 | |
| 15,903,000 | |
| 15,754,000 | |
| 15,183,000 | |
| 13,986,000 | |
| 34,660,000 | |
| 33,879,000 | |
| 33,508,000 | |
| 33,914,000 | |
| 11,743,000 | |
| 12,498,000 | |
| 12,372,000 | |
| 12,317,000 | |
| 13,196,000 | |
| 13,896,000 | |
| 16,326,000 | |
| 17,948,000 | |
| 18,242,000 | |
| 18,858,000 | |
| 19,981,000 | |
| 20,955,000 | |
| 21,872,000 | |
| 23,552,000 | |
| 23,465,000 | |
| 24,024,000 | |
| 26,340,000 | |
| 26,200,000 | |
| 28,867,000 | |
| 36,107,000 | |
| 41,882,000 | |
| 46,893,000 | |
| 47,014,000 | |
| 42,603,510 | |
| 41,092,766 | |
| 38,496,107 | |
| 38,518,244 | |
| 37,600,127 | |
| 35,542,885 | |
| 33,148,006 | |
| 29,597,264 | |
| 26,587,359 | |
| 22,160,623 | |
| 20,264,631 | |
| 19,349,672 | |
| 18,132,965 | |
| 17,466,942 | |
| 16,367,180 | |
| 15,037,030 | |
| 13,713,918 | |
| 13,081,578 | |
| 11,444,227 | |
| 9,587,968 | |
| 7,892,250 | |
| 5,456,703 | |
| 4,392,547 | |
| 3,603,114 | |
| 2,968,987 | |
| 2,303,226 | |
| 2,107,503 | |
| 1,884,887 | |
| 1,706,214 | |
| 1,555,772 | |
| 1,177,676 | |
| 971,465 | |
| 967,864 | |
| 1,192,587 | |
| 1,326,767 | |
| 1,497,996 | |
| 1,420,378 | |
| 1,272,905 | |
| 1,369,487 | |
| 1,329,001 | |
| 1,525,677 | |
| 1,518,144 | |
| 1,422,626 | |
| 1,358,063 | |
| 1,123,261 | |
| 1,037,497 | |
| 971,631 | |
| 906,288 | |
| 903,018 | |
| 923,352 | |
| 935,586 | |
| 1,067,455 | |
| 1,103,490 | |
| 1,160,120 | |
| 1,144,607 | |
| 1,343,028 | |
| 1,636,349 | |
| 2,007,996 |